Arvinas : Purchase Agreement (Form 8-K)

Other Events

As previously announced, on July 21, 2021, Arvinas, Inc. ('Arvinas') and Pfizer Inc. ('Pfizer') entered into a Stock Purchase Agreement (the 'Stock Purchase Agreement'). On September 9, 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the reportable transactions contemplated by the Stock Purchase Agreement (the 'HSR termination'). As a result of the HSR termination and satisfaction of the other closing conditions described in the Stock Purchase Agreement, on September 13, 2021, Arvinas issued and sold to Pfizer 3,457,815 shares of Arvinas' common stock at a price of $101.22 per share, for an aggregate purchase price of approximately $350 million, pursuant to the terms of the Stock Purchase Agreement.